SII’s Covovax gets DCGI’s nod for emergency use in children aged 7-11 yrs





The Drugs Controller General of India (DCGI) on Tuesday approved India’s first indigenously developed mRNA vaccine against COVID-19 manufactured by Gennova Biopharmaceuticals for restricted emergency use for those aged 18 years and above, official sources said on Tuesday.


While other mRNA vaccines require to be stored at sub-zero temperatures, Gennova’s mRNA vaccine can be stored at 2-8 degrees, an official source told PTI.


The drug regulator has also approved Serum Institute’s COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions.


The DCGI’s nod came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years and Gennova’s two dose m-RNA vaccine for 18 years and above, official sources said.


Prakash Kumar Singh, director, Government and Regulatory Affairs at (SII) had submitted an application to DCGI in this regard on March 16, official sources had said.


The expert panel, in its last meeting in April, had sought more data from the Pune-based firm over the application.


The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.


The country began inoculating children aged 12-14 years from March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.


The next phase of COVID-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.


India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.


The next phase of vaccination commenced from January 3 for adolescents in the age group of 15-18 years.


India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. Precaution dose of COVID-19 vaccines for all aged above 18 years began at private vaccination centres from April 10.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Comments are closed.